Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Vertiv Holdings Co — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.91 (market cap $4.49B), while Vertiv Holdings Co trades at $315.2 (market cap $117.38B). The key difference: Vertiv Holdings Co is far larger — about 26.1× ACADIA Pharmaceuticals Inc.'s market cap, and Vertiv Holdings Co pays a 0.08% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | VRT | |
|---|---|---|
Market Cap | $4.49B | $117.38B |
Sector | Health | Technology |
52-Week High | $28.06 | $376.23 |
52-Week Low | $20.06 | $120.72 |
Enterprise Value | $3.69B | $118.14B |
Dividend Yield | — | 0.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Vertiv Holdings (VRT) trades at $318.47, up 5.97% with strong bullish momentum. The stock shows robust fundamentals with Q1 2026 EPS beating estimates at $1.17 versus $1.00 expected, continuing a pattern of earnings outperformance. Technical indicators signal bullish momentum with the current price near pivot point resistance at $319. The company benefits from AI infrastructure demand, supported by recent manufacturing expansion in Malaysia and strategic acquisitions enhancing its data center portfolio.
Outlook remains positive with 94.7% analyst buy ratings and a $395.23 consensus price target implying 24% upside. Key risks include premium valuation multiples (P/E 80.02) and execution challenges in scaling operations. The AI infrastructure boom presents significant growth opportunity, though investors should monitor competitive pressures and macroeconomic conditions affecting data center spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
